Bio/Pharma News

The Natural Product Center of Excellence seeks to identify novel active compounds for new antibiotics.

Research was published describing a natural interferon-alpha for infection control and treatment of drug-resistant H7N9 influenza.

Forest's planned acquisition of Aptalis will enhance its business in gastrointestinal and cystic fibrosis therapies.

Eurofins acquires DDS business of Merck KGaA in order to expand discovery solutions and bioanalytical services.

GE acquires Thermo Fisher's HyClone cell culture media and sera products, gene modulation technologies, and magnetic beads businesses.

Janssen's donation program will improve access to the company's approved HIV medicines for children and adolescents in sub-Saharan Africa.

The Bristol-Myers Squibb Foundation is awarding 10 grants to fund programs for veterans and their families.

Baxter International recalls dextrose injection and four sodium chloride injections.

Encap will collaborate with Lipocine to manufacture Lipcine's oral testosterone product, LPCN 1021, for Phase III clinical trials.

Bind Therapeutics amends its development and commercialization collaboration agreement with Amgen.

Everett Laboratories acquires Quinnova Pharmaceuticals, a specialty pharmaceutical company.

Merck and GlaxoSmithKline begin clinical trial of pazopanib for the treatment of advanced renal-cell carcinoma.

Siemens enters agreement with Pfizer to commercialize diagnostic tests for therapeutic products across Pfizer's pipeline.

CMC Biologics and OnoSynergy form an agreement from cell-line development.

Pfizer appoints management changes to take effect in 2014.

Merck Serono, the biopharmaceutical division of Merck, has entered into an agreement on cancer drug development with the Spanish National Cancer Research Centre (CNIO) in Madrid.

Merck's new facility for aseptic production in Reinbek, Germany is scheduled to be completed in 2016.

AstraZeneca's MedImmune will collaborate with Johns Hopkins University in both biologics and small-molecule projects.

Moberg Pharma will acquire three OTC brands from Bayer HealthCare.

GSK forms the Oncology Clinical and Translational Consortium, a scientific research network comprised of six international cancer centers.

Johnson&Johnson will open a network of partnering offices across the UK.

AstraZeneca will receive $76 million in damages from Apotex Corp., Apotex, and Torpharm.

Bristol-Myers Squibb has elected Thomas Lynch, Jr., MD to its board of directors.

ScinoPharm completes new API manufacturing plant in Changshu, China.

Jill E. Sackman, D.V.M., PhD, senior consultant at Numerof & Associates, Inc. discusses the market forces impacting biopharmaceutical manufacturing

A roundup of developments in global health and sustainability from the bio/pharmaceutical industry, its suppliers, and other public and private organizations.

Additional companies join Merck KGaA and Neviah Genomics in the Israel BioIncubator.

The Indiana Biosciences Research Institute will accelerate collaboration and focus on human-health solutions.

Sanofi discontinues development for its investigational JAK2 inhibitor, fedratinib.

GSK and Amicus Therapeutics revise Fabry agreement entered into in July 2012.